<DOC>
	<DOCNO>NCT00515099</DOCNO>
	<brief_summary>Antithymocyte globulin ( e.g. , Thymoglobulin® ) antibody preparation commonly use treat prevent organ transplant rejection . The START trial aim determine whether antithymocyte globulin ( ATG ) treatment halt progression newly diagnose type 1 diabetes give within 12 week disease diagnosis .</brief_summary>
	<brief_title>Study Antithymocyte Globulin Treatment New-onset T1DM</brief_title>
	<detailed_description>Type 1 diabetes mellitus ( T1DM ) autoimmune disease immune system mistakenly attack insulin-producing beta cell pancreas . Without cell , body maintain proper blood glucose level response daily activity , eat exercise . Generally , time someone diagnose T1DM , person 's beta cell destroy - 15-40 % remain healthy still able produce insulin . Importantly , even small amount naturally produce insulin improve blood sugar control , make daily management diabetes less complicated , reduce risk long term complication . Preserving remain precious beta cell therefore goal START trial . The medication test START trial antithymocyte globulin ( e.g. , Thymoglobulin® ) , mixture specialize protein call antibody . ATG attach white blood cell know T cell , responsible immune system 's attack beta cell occur T1DM . ATG change T cell work , eliminate large proportion T cell bloodstream temporarily . Treatment new onset T1DM ATG therefore expect alter behavior T cell halt attack , also reduce T cell number , new T cell grow place learn accept beta cell , rather attack . Following initial screen appointment , eligible participant randomly assign one two group : Experimental Group receive study treatment Control Group receive placebo . Each participant 2 3 chance assign treatment group , 1 3 chance assign placebo . The START trial blind study , neither participant study physician know group individual assign . All participant receive intensive diabetes management . Participants group admit hospital 5-8 day receive infusion either study drug placebo . The duration study 2 year . Participants 8 follow-up appointment first year 4 visit second year . Most visit last 1- 2 hour . A review interval health , physical exam , assessment diabetes control include recent 5 day insulin use blood sugar ( e.g. , glucose ) testing , blood collection laboratory test occur visit . Four visit last 5 hour , participant undergo mixed-meal tolerance testing ( MMTT ) . This involve drink special drink , similar milkshake , blood specimen take 4-hour period . Subjects reimburse travel parking expense , receive compensation participation longer mixed meal tolerance test visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Diagnosis type 1 diabetes ( accord American Diabetes Association [ ADA ] criterion ) within100 day enrollment Positive one autoantibody ( antiglutamic acid decarboxylase [ GAD ] , antiinsulin , IA2 autoantibody ) Peak stimulate Cpeptide level &gt; 0.4 pmol/mL &gt; 1.2ng/mL follow MMTT Serologic evidence prior EpsteinBarr virus ( EBV ) infection ( EBV seropositive ) Willing use acceptable form contraception Any sign active infection ( e.g. , hepatitis , tuberculosis , EBV , cytomegalovirus ( CMV ) , toxoplasmosis ) screen Positive human immunodeficiency virus ( HIV ) , tuberculosis , hepatitis B surface antigen ( HBsAg ) screen Prior history significant cardiac disease , congestive heart failure , arrhythmia , structural defect , suspicion thereof Use glucocorticoids 28 day prior study entry ; topical use glucocorticoid Use diabetes medication ( insulin ) may affect glucose homeostasis , metformin , sulfonylurea , thiazolidinediones , amylin Evidence liver dysfunction Evidence kidney disease Pregnancy plan become pregnant Leukopenia ( &lt; 3,000 leukocytes/µL ) , neutropenia ( &lt; 1,500neutrophils/µL ) , lymphopenia ( &lt; 800 lymphocytes/µL ) , thrombocytopenia ( &lt; 125,000 platelets/µL ) . Prior treatment rabbit ATG know hypersensitivity exposure rabbit seraderived product Vaccination live virus within last 6 week enrollment Prior current therapy know cause significant , ongoing change course T1DM immunologic status Any condition may compromise study participation may confound interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>New-onset Type 1 Diabetes Mellitus</keyword>
	<keyword>New-onset T1DM</keyword>
	<keyword>New-onset Type 1 Diabetes</keyword>
	<keyword>New-onset T1D</keyword>
	<keyword>Newly Diagnosed Type 1 Diabetes Mellitus</keyword>
	<keyword>Autoimmune diabetes</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Rabbit antithymocyte globulin</keyword>
</DOC>